The future burden of CKD in the United States: a simulation model for the CDC CKD Initiative.

BACKGROUND Awareness of chronic kidney disease (CKD), defined by kidney damage or reduced glomerular filtration rate, remains low in the United States, and few estimates of its future burden exist. STUDY DESIGN We used the CKD Health Policy Model to simulate the residual lifetime incidence of CKD and project the prevalence of CKD in 2020 and 2030. The simulation sample was based on nationally representative data from the 1999 to 2010 National Health and Nutrition Examination Surveys. SETTING & POPULATION Current US population. MODEL, PERSPECTIVE, & TIMELINE Simulation model following up individuals from current age through death or age 90 years. OUTCOMES Residual lifetime incidence represents the projected percentage of persons who will develop new CKD during their lifetimes. Future prevalence is projected for 2020 and 2030. MEASUREMENTS Development and progression of CKD are based on annual decrements in estimated glomerular filtration rates that depend on age and risk factors. RESULTS For US adults aged 30 to 49, 50 to 64, and 65 years or older with no CKD at baseline, the residual lifetime incidences of CKD are 54%, 52%, and 42%, respectively. The prevalence of CKD in adults 30 years or older is projected to increase from 13.2% currently to 14.4% in 2020 and 16.7% in 2030. LIMITATIONS Due to limited data, our simulation model estimates are based on assumptions about annual decrements in estimated glomerular filtration rates. CONCLUSIONS For an individual, lifetime risk of CKD is high, with more than half the US adults aged 30 to 64 years likely to develop CKD. Knowing the lifetime incidence of CKD may raise individuals' awareness and encourage them to take steps to prevent CKD. From a national burden perspective, we estimate that the population prevalence of CKD will increase in coming decades, suggesting that development of interventions to slow CKD onset and progression should be considered.

[1]  M. Engelgau,et al.  Changes in incidence of diabetes in U.S. adults, 1997-2003. , 2006, American journal of preventive medicine.

[2]  Haifeng Guo,et al.  US Renal Data System 2012 Annual Data Report. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  Rury R Holman,et al.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). , 2003, Kidney international.

[4]  Desmond E. Williams,et al.  Cost-effectiveness of screening for microalbuminuria among African Americans. , 2012, Journal of the American Society of Nephrology : JASN.

[5]  N. Powe,et al.  Screening for Proteinuria in US Adults , 2017 .

[6]  Essam Elsayed,et al.  Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  Foreman,et al.  The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. , 2013, JAMA.

[8]  Jerry Yee,et al.  Chronic kidney disease awareness among individuals with clinical markers of kidney dysfunction. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[9]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[10]  B. Astor,et al.  Age and association of kidney measures with mortality and end-stage renal disease. , 2012, JAMA.

[11]  Michael M. Engelgau,et al.  Prevalence of Diabetes and Impaired Fasting Glucose in Adults in the U.S. Population , 2006, Diabetes Care.

[12]  Desmond E. Williams,et al.  A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  Milton C Weinstein,et al.  Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  Sudha Seshadri,et al.  Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. , 2002, JAMA.

[15]  Charles E. McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[16]  Martin Krapcho,et al.  SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .

[17]  E. Arias,et al.  United States life tables, 2005. , 2010, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[18]  L. Goldman,et al.  The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. , 1997, JAMA.

[19]  J. Coresh,et al.  Lifetime incidence of CKD stages 3-5 in the United States. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  Desmond E. Williams,et al.  A health policy model of CKD: 1. Model construction, assumptions, and validation of health consequences. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  D. Rolla,et al.  Left ventricular hypertrophy in nondiabetic predialysis CKD. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  S. Derose,et al.  Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  Mark D. Huffman,et al.  Heart disease and stroke statistics--2013 update: a report from the American Heart Association. , 2013, Circulation.

[24]  G. Cerasola,et al.  Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. , 2007, Clinical nephrology.

[25]  R. Sacco,et al.  Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community , 1994, Neurology.

[26]  K. Anderson,et al.  Cardiovascular disease risk profiles. , 1991, American heart journal.

[27]  J. Stockman,et al.  A New Equation to Estimate Glomerular Filtration Rate , 2011 .

[28]  J. Coresh,et al.  Prevalence of chronic kidney disease in the United States. , 2007, JAMA.

[29]  K. Lemley,et al.  Determinants of glomerular hypofiltration in aging humans. , 2003, Kidney international.

[30]  Stephen W. Sorensen,et al.  Lifetime risk for diabetes mellitus in the United States. , 2003, JAMA.

[31]  Desmond E. Williams,et al.  Medical costs of CKD in the Medicare population. , 2013, Journal of the American Society of Nephrology : JASN.